| abstract |
The present invention refers to the biotechnological field, more particularly to the use of the calcineurin subunit Αβ1 isoform (CnΑβ1) for the treatment or prevention of ischemic and non¬ ischemic heart disease. Specifically, the present invention refers to a virion-free nucleic acid construct comprising a nucleotide sequence selected from the list consisting of: a. A nucleic acid sequence encoding SEQ ID No 1, or the complementary sequence of said nucleic acid sequence; b. a nucleic sequence encoding a peptide comprising a fragment of SEQ ID No 1, wherein said fragment consists of SEQ ID No 2, or the complementary sequence of said nucleic acid sequence; or c. a variant of a) or b) which encodes a peptide which is at least 80% homologous to SEQ ID No 1 or SEQ ID No 2 based on amino acid identity; wherein the nucleotide sequence is operably linked to control elements which direct the transcription and translation of the nucleotide sequence and wherein the nucleotide sequence operably linked to the control elements is flanked by a 5' and a 3' adeno-associated virus inverted terminal repeat (AAV ITRs). |